Physician profile
Maria M Wiscovitch Guzman
NPI 1316023294
$8,075.03
in general payments reported to CMS, 2019-2025
28 companies · $1,682 in 2025
The $1,682 reported for 2025 was more than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $189 · 2021: $1,057 · 2022: $1,893 · 2023: $1,122 · 2024: $1,410 · 2025: $1,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,130 · Education: $84.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,129.69 |
| Education | $84.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,414.82 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $1,338.70 | 2019-2025 | Rytary, Crexont, Ongentys |
| Emd Serono, INC. | $752.53 | 2022-2025 | |
| Abbvie INC. | $697.21 | 2021-2025 | Qulipta, Ubrelvy, Duopa |
| Biogen, INC. | $608.11 | 2019-2025 | Vumerity, Skyclarys, Tysabri |
| Alexion Pharmaceuticals, INC. | $345.20 | 2022-2025 | Ultomiris |
| Pbg Puerto Rico LLC | $316.62 | 2019-2025 | |
| Ucb, INC. | $295.83 | 2019-2024 | Zilbrysq |
| Genzyme Corporation | $276.57 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $246.73 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $184.84 | 2021-2024 | Zeposia |
| Amgen INC. | $144.92 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $144.36 | 2025 | Wainua |
| Eli Lilly Export S.A. Puerto Rico Branch | $142.12 | 2020-2024 | Emgality, Kisunla |
| Banner Life Sciences, LLC | $124.95 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $124.95 | 2025 | |
| Sunovion Pharmaceuticals INC. | $122.58 | 2021-2022 | |
| Horizon Therapeutics Plc | $118.71 | 2022 | |
| Acorda Therapeutics, INC | $117.04 | 2019 | |
| Greenwich Biosciences, INC. | $110.02 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $105.92 | 2022 | |
| Lilly USA, LLC | $97.48 | 2022 | |
| Adamas Pharmaceuticals, INC. | $64.68 | 2021 | |
| Ani Pharmaceuticals, INC. | $47.44 | 2024-2025 | Purified Cortrophin Gel |
| Medtronic, INC. | $45.71 | 2019 | |
| Novartis Pharmaceuticals Corporation | $35.24 | 2023-2024 | |
| Pfizer Pharmaceuticals LLC | $30.01 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Wiscovitch Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.